Enza Cestone, Eleonora Spartà, Vincenzo Nobile*, Vincenzo Zaccaria*, Francesco Pappalardo, Violetta Insolia, Giuseppe Antonio Malfa, Daniela Buonocore and Maurizia Dossena
Androgenetic Alopecia (AGA) is a progressive hair loss type affecting up to 80% of men and 50% of women. The putative mechanisms in the pathogenesis of AGA include microinflammation, premature cell senescence, oxidative stress, follicle vascular changes and altered sensitivity of hair follicles to androgens. A randomized, double-blind, placebo-controlled trial was carried out on 86 male subjects with AGA from II to III vertex (Hamilton-Norwood). Product efficacy was measured after 3, 6 months of product intake and 1-month post-supplementation. The hair cycle parameters measurement by phototricogram were integrated by the global photography assessment and the self-assessment questionnaire. The results showed an increase of the total hair density and the % of hair in anagen phase with a simultaneous decrease in the % of hair in telogen phase; as consequence the anagen/telogen ratio was improved of about 45.7% and 85.8% at 3 and 6 mo, respectively. The instrumental data were confirmed by the clinical analysis carried out by a board-certified dermatologist and by the self-assessment questionnaire. The obtained improvements were also maintained 1-month post-supplementation. The intake of 250 mg of ActrisaveTM improved the hair life cycle increasing hair growth, density and slowing down hair loss in men with mild-to-moderate androgenetic alopecia.
HTML PDFShare this article
Journal of Cosmetology & Trichology received 180 citations as per Google Scholar report
